In a randomized, blinded, controlled phase II trial, the AE37 peptide vaccine was applied in HLA-A2 negative, HER2/neu-expressing tumor (IHC 1–3+), disease-free node positive, and high-risk node negative breast cancer patients enrolled after standard-of-care therapy. Here, ERBB2 is linked to neoplasm.